Array BioPharma (ARRY) Posts Mixed Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.26 -4.4%
EPS Growth %: -70.0%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: -70.0%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Array BioPharma, Inc. (Nasdaq: ARRY) reported Q3 loss of $0.20, $0.05 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $19.58 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at BMO Capital
- Array Technologies (ARRY) PT Lowered to $7 at JPMorgan
- American Airlines (AAL) Tops Q3 EPS by 5c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
